Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The company highlighted that about 90% of proteins associated with diseases cannot be targeted with traditional therapies due ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

This metric takes into account a company's operating cash flow and ... These are only a few of the key metrics included in Takeda Pharmaceutical Co.'s strong Value grade, but they help show ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Takeda Pharmaceutical Stock Up 1.6 % Shares of Takeda Pharmaceutical stock opened at $14.08 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08 ...

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. Healthcare, which includes numerous businesses that ...